Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Khiron Life Sciences Corp KHRNF


Primary Symbol: V.KHRN.H Alternate Symbol(s):  V.KHRN.W.H | KHRWF

Khiron Life Sciences Corp. is a Canada-based medical cannabis company with core operations in Latin America. The Company has its wholly owned medical health clinics and telemedicine platforms. The Company has two product lines: Medical Cannabis Products and Health Services. It sells branded medical cannabis products to patients with medical conditions. Under the Medical Cannabis Products line... see more

TSXV:KHRN.H - Post Discussion

Khiron Life Sciences Corp > Happy to average down at these prices!!
View:
Post by ORTsnort on Oct 28, 2020 4:47pm

Happy to average down at these prices!!

Thank you very much. They're going to announce 5000 prescriptions any week now
Comment by Benedictus on Oct 28, 2020 10:17pm
Have you done the math on script build in Columbia? 5000 or 10000 are a nice beginning but in a country with an annual per capita income of sub $7000 and expected revenue of around $350 or less for annual sales to loyal clients/patients, these early numbers just aren't going to move the market imo. If Columbia announces insurance coverage for medical cannabis or Mexico legalizes - those ...more  
Comment by CousinAdam on Oct 29, 2020 2:56am
I would tend to agreed with the analysis of the Colombian sales truly moving the needle on the stock price, COVID has had huge impact on the country and it's difficult to see this having any meaningful impact on the revenue.  As for project 2021, while the company keeps touting it, looking into the project, it is interesting that there doesn't seem to be any major suppliers tied to ...more  
Comment by Benedictus on Oct 29, 2020 4:24am
You bring up several points/opinions worth discussing further: the project 21 is $200 per month or $2400 per patient per annum. I would imagine most customers will maximize this benefit. Who turns away free money? Naprawa has acknowledged on the last quarterly presentation they're expecting overall margins in the 50% range across all markets and Tejinder acknowledged on one of his webinars ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities